Research
Hormonal
In obese men with metabolic syndrome, short-term weight loss via a hypocaloric low-fat diet increases LDL apoB-100 catabolism, thereby lowering plasma LDL cholesterol concentrations.
For men with metabolic syndrome, losing weight through a calorie-restricted, low-fat diet improves heart health by speeding up how your body clears LDL cholesterol from your blood. While this might not raise your HDL numbers, the reduction in LDL is a significant benefit for cardiovascular risk.
GoodSupportsHIGH confidence
Weight loss significantly increased the catabolism of LDL apoB-100 (-27%, P < 0.05) but did not affect production... In obese men with metabolic syndrome, weight loss with a low-fat diet decreases the plasma LDL apoB-100 concentration by increasing the catabolism of LDL apoB-100
Why this rating
Randomized controlled trial with stable isotope kinetic modeling, though limited to a specific male demographic.
Source
Effect of Weight Loss on LDL and HDL Kinetics in the Metabolic Syndrome
T Ng et al. · Diabetes Care · 2007
DOI 10.2337/dc07-0768
rct · n=35Cited 101×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- The improvement in LDL kinetics (increased catabolism) following weight loss is inversely correlated with reductions in plasma Retinol-Binding Protein-4 (RBP-4).Good
- In obese men with metabolic syndrome, weight loss decreases HDL apoA-I production and catabolism by equal amounts, resulting in no net change in plasma HDL cholesterol concentrations.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →